Watch INM. Know when insiders buy.
One email the day a filing lands. Free.
INM
InMed Pharmaceuticals Inc.
1.28
+0.00 +0.00%
USD · Sep 17, 08:20 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
81
PASS · insiders 61, shorts 100
Insiders, 90 days
+$118K
net buying · 3 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.6MNET CASH —52W 0.62 – 2.46SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | — | — | — | — | −$5.8M | — | -1.43 | −$3M | — | — | Sep 9 |
| Q3 2026 · Mar 31 | — | — | — | — | −$3M | — | -0.73 | −$1.7M | — | — | May 6 |
| Q2 2026 · Dec 31 | $820K | −26.2% | 22.5% | — | −$2M | — | -0.51 | −$2.4M | — | — | May 6 |
| Q1 2026 · Sep 30 | $1.1M | −11.4% | 36.0% | — | −$1.7M | — | -0.44 | −$1.6M | — | — | May 6 |
| Q4 2025 · Jun 30derived | $1.3M | +1.7% | 44.2% | — | −$1.8M | — | -0.43 | −$2.1M | — | — | Sep 9 |
| Q3 2025 · Mar 31 | $1.3M | +7.6% | 13.9% | — | −$2.1M | — | -1.94 | −$1.7M | — | — | May 6 |
| Q2 2025 · Dec 31 | $1.1M | −10.4% | 41.5% | — | −$2.6M | — | -3.64 | −$2.5M | — | — | May 6 |
| Q1 2025 · Sep 30 | $1.3M | +40.2% | 39.0% | — | −$1.7M | — | -2.71 | −$1.8M | — | — | May 6 |
| Q4 2024 · Jun 30derived | $1.3M | — | 36.3% | — | −$1.9M | — | -3.66 | −$1M | $0 | −$1M | Sep 23 |
| Q3 2024 · Mar 31 | $1.2M | — | 24.7% | — | −$1.7M | — | -3.58 | −$1.9M | $2 | −$1.9M | May 12 |
| Q2 2024 · Dec 31 | $1.2M | — | 26.1% | — | −$1.5M | — | -3.71 | −$1.8M | — | — | May 12 |
| Q1 2024 · Sep 30 | $902K | — | 2.4% | −$2.5M | −$2.5M | — | -15.24 | −$2.2M | — | — | May 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | — | — | — | −$12.6M | — | -3.12 | −$8.6M | — | — | — | — |
| FY2025 · to Jun 30 | $4.9M | 34.5% | — | −$8.2M | -165.1% | -8.36 | −$8.1M | — | — | — | — |
| FY2024 · to Jun 30 | $4.6M | 23.9% | — | −$7.7M | -166.9% | -20.14 | −$7M | $9K | −$7M | — | — |
| FY2023 · to Jun 30 | $4.1M | 33.9% | −$7.9M | −$7.9M | -192.2% | -3.25 | −$7.3M | $160K | −$7.4M | — | — |
| FY2022 · to Jun 30 | $1.1M | 49.9% | −$18.6M | −$18.6M | -1707.3% | -33.17 | −$15.6M | $39K | −$15.6M | — | — |
| FY2021 · to Jun 30 | $1.9M | — | −$10.2M | −$10.2M | -535.9% | -37.96 | −$9.8M | $2K | −$9.8M | — | — |
Every number comes from InMed Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.